EMA Knocks Back Pfizer’s Xeljanz For Rheumatoid Arthritis and Otsuka’s Delamanid For TB
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA has rejected Pfizer’s tofacitinib for the second time on safety grounds and Otsuka’s delamanid due to a short trial length.
You may also be interested in...
Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs
Pfizer's Xeljanz (tofacitinib) has finally won a green light from the European Medicines Agency's CHMP for treating rheumatoid arthritis, but its two previous rejections by the panel on safety grounds might curb sales.
India’s Drug Advisory Body Calls For Larger Study To Approve Pfizer’s Xeljanz
The New Drug Advisory Committee said the number of patients enrolled in Pfizer’s Xeljanz trials was not statistically significant to recommend marketing authorization.
EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products
The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.